This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Accelovance Expansion Continues With Acquisition Of Radiant Development, The CRO Division Of Radiant Research

ROCKVILLE, Md., March 6, 2013 /PRNewswire-USNewswire/ -- Accelovance, Inc. announced today the acquisition of Radiant Development, the CRO division of Radiant Research. This is the latest development in an expansion strategy by the Maryland based CRO that caters to Biotech and small/mid Pharma Sponsors. Terms of the transaction were not disclosed. 

Accelovance is a patient centric CRO offering innovative solutions to meet the needs of its clients. Much of the company's CRO growth has been in the vaccine, infectious disease, and oncology markets. The addition of Radiant Development broadens Accelovance's ability to provide high quality services across a range of therapeutic areas. Radiant Development has performed studies in areas including cardiovascular, men's and women's health, rheumatology, dermatology, oncology and medical device.  Radiant Development also has specialized expertise in consumer health and nutrition.

"We are thrilled to have 100% of the Radiant team led by Vita Lanoce as part of our company.  Core values focused on meeting our client needs, open communication and relationships built on honesty and trust are important similarities between our organizations," remarked Stephen J. Trevisan, Accelovance President and Chief Executive Officer.

Operating out of locations in Stuart, Florida, Chicago, Illinois, and Durham, North Carolina, Radiant Development has managed over 200 research studies since its inception.  Additionally, the company has established strategic partnerships in Europe and Asia to offer clients global study capabilities.  Radiant Development will operate as a division of Accelovance, providing full service clinical capabilities including: project management and clinical monitoring, medical, safety and pharmacovigilance, regulatory consulting, medical writing, data management and statistical services.

"With a shared vision of an innovative approach to execution, exceptional customer service, and focus on providing value to our clients, Radiant Development is delighted to join forces with Accelovance to offer expanded leading edge service solutions to our clients," said Vita Lanoce, Senior Vice President of Development.

Current customers, employees and stake holders of Radiant Development should expect the continued high level of quality, service and performance they are accustomed to receiving.  This includes an ongoing, preferred provider relationship with the Radiant Research and Clinical Research Advantage site network.     

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,098.45 +18.88 0.11%
S&P 500 2,003.37 +6.63 0.33%
NASDAQ 4,580.2710 +22.5760 0.50%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs